Last reviewed · How we verify
NCT05117125: VAPmarkers
Biomarkers for Ventilator-associated Pneumonia
trial testing Heparin-binding protein in Pneumonia, Ventilator-Associated in 1,000 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Region Skane |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 15 October 2021 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2028 |
| Sites | 5 locations across Portugal, Sweden, Norway |
Drugs / interventions tested
- Heparin-binding protein
- Interleukin-26
- Microbiome
- Bacterial transcriptome
- Proteome
Conditions studied
- Pneumonia, Ventilator-Associated — all drugs for Pneumonia, Ventilator-Associated →
Sponsor
Region Skane — full company profile →
Who can join
18 and older, any sex, with Pneumonia, Ventilator-Associated. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
ClusterVAP: study protocol for multicentre proteomic endotyping of ventilator-associated pneumonia.
Sjövall F, Póvoa P, Petersson J, Koulenti D, et al · · 2026 · PMID 41802817 · DOI 10.1136/bmjresp-2025-003830
Verify or expand the search:
- PubMed search for NCT05117125
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pneumonia, Ventilator-Associated
Currently open trials in the same condition.
- NCT06467864 — Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological · recruiting
- NCT07052604 — Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients · recruiting
- NCT05843786 — Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients · Phase 3 · recruiting
Other Region Skane trials
Trials by the same sponsor.
- NCT07511673 — The Study is a Randomised Clinical Trial (RCT) to Test if Preoperative Dental Screening is Superior to no Preoperative D · NA · not yet recruiting
- NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
- NCT07494669 — Proteomics and Physiological Parameters Predicting Complications After Colorectal Cancer Surgery · not yet recruiting
- NCT07462351 — System-integrated Point-of-Care Ultrasound in Breast Cancer Screening · NA · recruiting
- NCT06975696 — Fusion Imaging in Endovascular Thrombectomy for Acute Ischemic Stroke · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05117125 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region Skane
- Last refreshed: 15 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05117125.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing